VRTX Vertex Pharmaceuticals Incorporated

Price (delayed)

$267.15

Market cap

$69.27B

P/E Ratio

45.74

Dividend/share

N/A

EPS

$5.84

Enterprise value

$66.21B

Sector: Healthcare
Industry: Biotechnology
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Highlights

The gross profit has grown by 48% YoY and by 16% from the previous quarter
VRTX's revenue is up by 48% YoY and by 16% QoQ
The EPS has declined by 31% year-on-year but it has increased by 28% since the previous quarter
Vertex Pharmaceuticals's net income has decreased by 30% YoY but it has increased by 28% QoQ
The price to earnings (P/E) is 41% more than the last 4 quarters average of 32.5
Vertex Pharmaceuticals's quick ratio has decreased by 8% YoY

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
259.28M
Market cap
$69.27B
Enterprise value
$66.21B
Valuations
Price to earnings (P/E)
45.74
Price to book (P/B)
10.72
Price to sales (P/S)
14.4
EV/EBIT
36.99
EV/EBITDA
34.91
EV/Sales
13.74
Earnings
Revenue
$4.82B
EBIT
$1.79B
EBITDA
$1.9B
Free cash flow
$1.98B
Per share
EPS
$5.84
Free cash flow per share
$7.63
Book value per share
$24.92
Revenue per share
$18.55
TBVPS
$28.83
Balance sheet
Total assets
$8.89B
Total liabilities
$2.43B
Debt
$532.95M
Equity
$6.46B
Working capital
$3.91B
Liquidity
Debt to equity
0.08
Current ratio
3.54
Quick ratio
3.27
Net debt/EBITDA
-1.61
Margins
EBITDA margin
39.4%
Gross margin
87.2%
Net margin
31.4%
Operating margin
34.2%
Efficiency
Return on assets
19%
Return on equity
26.4%
Return on invested capital
60.5%
Return on capital employed
24.3%
Return on sales
37.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$4.82B
Gross profit
$4.2B
Operating income
$1.65B
Net income
$1.51B
Gross margin
87.2%
Net margin
31.4%
The operating income has surged by 110% year-on-year and by 37% since the previous quarter
VRTX's net margin has shrunk by 52% YoY but it is up by 11% QoQ
The gross profit has grown by 48% YoY and by 16% from the previous quarter
VRTX's revenue is up by 48% YoY and by 16% QoQ

Valuation

What is Vertex Pharmaceuticals stock price valuation
P/E
45.74
P/B
10.72
P/S
14.4
EV/EBIT
36.99
EV/EBITDA
34.91
EV/Sales
13.74
The price to earnings (P/E) is 41% more than the last 4 quarters average of 32.5
The EPS has declined by 31% year-on-year but it has increased by 28% since the previous quarter
The stock's price to book (P/B) is 37% less than its 5-year quarterly average of 17.0 but 18% more than its last 4 quarters average of 9.1
The equity has grown by 37% YoY and by 6% from the previous quarter
VRTX's revenue is up by 48% YoY and by 16% QoQ
The price to sales (P/S) is 11% more than the last 4 quarters average of 13.0 but 11% less than the 5-year quarterly average of 16.1

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on invested capital has surged by 80% year-on-year and by 26% since the previous quarter
The return on equity has dropped by 55% year-on-year but it has grown by 18% since the previous quarter
VRTX's return on assets has dropped by 52% year-on-year but it is up by 19% since the previous quarter
The return on sales has surged by 51% year-on-year and by 6% since the previous quarter

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's total assets has increased by 36% YoY and by 7% QoQ
The total liabilities has increased by 34% YoY and by 9% QoQ
VRTX's debt is 92% lower than its equity
The debt to equity fell by 39% YoY and by 11% QoQ
The equity has grown by 37% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.